SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Ruilope, L. M
Right arrow Articles by Schiffrin, E. L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ruilope, L. M
Right arrow Articles by Schiffrin, E. L
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Blood Pressure Medicines
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients?

Luis M Ruilope

Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain, Luis_M_Ruilope @teleline.es

Julian Segura

Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain

Ernesto L Schiffrin

Multidisciplinary Research Group on Hypertension, Clinical Research Institute, University of Montréal, Montréal, Quebec, Canada

Blockade of the effects of angiotensin II (Ang II) by using an angiotensin-converting enzyme (ACE) inhibitor has been proven to be of value in Type 1 diabetic nephropathy and in non-diabetic renal disease. Evidence in favour of Ang II blockade in Type 2 diabetic patients with renal damage is still lacking for ACE inhibitors (ACE-Is), while recent data indicate that angiotensin receptor blockers (ARBs) could be the drugs of choice in this situation. On the other hand, renal damage from the onset of disease is accompanied by a very significant increment in global cardiovascular risk. This fact, as well as that of simultaneous renal and cardiovascular protection, have to be considered for drug selection. In this sense, ACE-Is have been shown to be the drugs of choice when secondary cardiovascular prevention is required, while the evidence in primary prevention in hypertensive patients has been shown with losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. All these facts led to the conclusion that both ACE-Is and ARBs can be considered when both renal and cardiovascular protection are aimed for in Type 2 diabetic patients.

Key Words: ACE inhibition • angiotensin receptor antagonists • losartan • irbesartan • proteinuria • microalbuminuria • renal function • cardiovascular disease

References

  • Golan L., Birkmeyer JD, Welch G. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 1999;131:660-7.[Abstract/Free Full Text]
  • Kshirsagar AV, Joy MS, Hogan SL et al. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease:A systematic overview of randomised placebo-controlled trials. Am J Kidney Dis 2000;35:695-707.[Web of Science][Medline] [Order article via Infotrieve]
  • The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 200:370-3 Intern Med 2001;134:370-9.
  • Brenner BM, Cooper ME, De Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:8619.
  • Lewis ED, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.[Abstract/Free Full Text]
  • Parving H-H., Lehnert H., Bröchner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345: 870-8.[Abstract/Free Full Text]
  • Parving HH Initiation and progression of diabetic nephropathy. N Engl J Med 1996;335:1682-3.[Free Full Text]
  • US Renal Data System: USRDS 1999 Annual Data Report. National Institutes of Health. National Institute of Diabetes and Kidney Diseases. Bethesda, MD, April 1999.
  • Ruilope LM,Van Veldhuisen D., Ritz E. et al. Renal function: the cinderella of cardiovascular risk profile. J Am Coll Cardiol 2001;38:1782-7.[Abstract/Free Full Text]
  • The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, andTreatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46.[Abstract/Free Full Text]
  • Guidelines Subcommittee, World Health Organisation-International Society of Hypertension Guidelines for the management of hypertension. J Hypertens 1999;17:151-83.[Web of Science][Medline] [Order article via Infotrieve]
  • Bakris GL, Williams M., Dworkin L. et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000;36:646-61.[Web of Science][Medline] [Order article via Infotrieve]
  • Ruilope LM, Campo C., Rodicio JL Blood pressure control, proteinuria and renal outcome in chronic renal failure. Curr Opin Nephrol Hypertens 1998;7:145-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Ruilope LM, Schiffrin E. Blood pressure control and benefits of antihypertensive therapy: does it make a difference what agent we use? Hypertension 2001;38:537-42.[Abstract/Free Full Text]
  • The PROCOPA Study Group. Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomised double-blind trial. J Hypertens 2002;20: 729-37.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998;317:713-20.[Abstract/Free Full Text]
  • Ruilope LM, Salvetti A., Jamerson K. et al. Renal function and intensive lowering of blood pressure in the hypertensive subjects of the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol 2001;12:218-25.[Abstract/Free Full Text]
  • Estacio RO, Jeffers BW, Hiatt WR et al.The effect of nisoldipine as compared with enalapril on cardiovascular events in patients with non-insulin-dependent diabetes and hypertension. NEnglJMed 1998;338:645-52.[Abstract/Free Full Text]
  • Voyaki SM, Staessen JA, Thijs L. et al. Follow-up of renal function intreated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (SystEur) Trial Investigators. J Hypertens 2001;19:511-19.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mann JFE, Gerstein HC, Pogue J. et al. Renal insufficiency as predictor of cardiovascular outcomes and impact of ramipril: the HOPE randomisation trial. Ann Intern Med 2001;134:629-36.[Abstract/Free Full Text]
  • Schrier RW, Estacio RO, Esler A., Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61:1086-97.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ravid M., Lang R., Rachmani R., Lischner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med 1996;156:286-9.[Abstract/Free Full Text]
  • Chan JC, Cockram CM, Nicholls MG et al. Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. BMJ 1992;305:98-105.
  • Lacourciere Y., NadeauA, Poirier L.,Tancrede G. Captopril or conventional therapy in hypertensive type II diabetics. Three year analysis. Hypertension 1993;21:786-94.[Abstract/Free Full Text]
  • Sano T., KawamuraT, Matsumae H. et al. Effects of long-term enalapril treatment on persistent microalbuminuria in well controlled hypertensive and normotensive NIDDM patients. Diabetes Care 1994;17:420-4.[Abstract]
  • Lebovitz HE,Wiegmann TB, Cnaan A. et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline microalbuminuria. Kidney Int 1994;45(suppl):S150-S155.[CrossRef][Web of Science]
  • Bakris GL, Copley JB, Vicknair N. et al. Calcium Channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996;50: 1641-50.[Web of Science][Medline] [Order article via Infotrieve]
  • Agardh CD, Garcia Puig J., Charbonnel B. et al. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 1996;10:185-92.[Web of Science][Medline] [Order article via Infotrieve]
  • Melbourne Diabetic Nephropathy Study Group. Comparison between perindopril and nifedipine in normotensive patients with incipient diabetic nephropathy. BMJ 1991; 302:210-16.[Abstract/Free Full Text]
  • Velussi M., Brocco E., Frigato F. et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996;45:216-22. [Abstract]
  • Ruggenenti P., Mosconi L., Bianchi L. et al. Long-term treatment with either enalapril or nitrendipine stabilises albuminuria and increases glomerular filtration rate in non-insulindependent diabetic patients. Am J Kidney Dis 1994;24:753-61.[Web of Science][Medline] [Order article via Infotrieve]
  • Nielsen ES, Rossing P., Gall MA et al. Long-term effects of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997;46: 1182-8.[Abstract]
  • Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ravid M., Brosch D., Levi Z. et al. Use of enalapril to attenuate decline in renal function in normotensive normoalbuminuric patients with type 2 diabetes mellitus: a randomised controlled trial. Ann Intern Med 1998;128:982-8.[Abstract/Free Full Text]
  • Parving H-H., Hovind P., Rossing K. et al. Evolving strategies for renoprotection: diabetic nephropathy. Curr Opin Nephrol Hypertens 2001;10:515-22.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Chalmers JP Ongoing trials of angiotensin-converting enzyme inhibition: what they can tell us. Am J Hypertens 2001; 14:270S-275S.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Weber M. Angiotensin II receptor blockers and cardiovascular outcomes: the evidence now and in the future. JRAAS 2001;2(suppl 2):S12-S16.
  • Mogensen CE, Neldam S., Tikkanen I. et al., for the CALM study group. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-4.[Abstract/Free Full Text]
  • Laverman GD, Navis G., Henning RH, de Jong PE, de Zeeuw D. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 2002;62:1020-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nakao N., Yoshimura A., Morita H., Takada M., Kayano T., Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in nondiabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117-24.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Dahlöf B., Devereux RB, Julius S. et al. Characteristics of 9194 patients with left ventricular hypertrophy.The LIFE Study. Hypertension 1998;32:989-97.[Abstract/Free Full Text]
  • Kjeldsen SE, Julius S., Brunner H. et al. Characteristics of 15,314 hypertensive patients at high coronary risk.The VALUE trial. Blood Press 2001;10:83-91.
  • Kaplan NM Clinical Hypertension. Eds. Williams & Wilkins. Baltimore 1998.
  • Waeber B., Nussberger J., Brunner HR Angiotensin converting enzyme inhibitors in hypertension. In: Laragh JH, Brenner BM (eds.). Hypertension. Pathophysiology, Diagnosis and Management. New York: Raven Press, 1995;2861-75.
  • Campo C., Segura J., Fernández ML, Guerrero L., Christiansen H., Ruilope LM A prospective comparison of four antihypertensive agents in daily clinical practice. J Clin Hypertens 2001;3:139-44.[CrossRef]
  • Dahlöf B., Pennert K., Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients.A metaanalysis of 109 treatmentstudies.AmJHypertens 1992;5:95-110.
  • Schmieder RE, Marttus P., Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomised double-blind studies.JAMA 1996;275:1507-13.[Abstract/Free Full Text]
  • Swedberg K., Held P., Kjekshus J., Rasmussen K., Ryden L., Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327:678-84.[Abstract]
  • Gruppo Italiano per lo Studio della Sopravivenza nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.[Web of Science][Medline] [Order article via Infotrieve]
  • ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Pfeffer MA, Braunwald E., Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.[Abstract]
  • The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.[Abstract]
  • The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.[Abstract]
  • Ruggenenti P., Perna A., Gherardi G. et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet 1998;352: 1252-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998;317:703-13.[Abstract/Free Full Text]
  • Hansson L., Lindholm LH, Niskaken L. et al. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-16.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hansson L., Lindholm LH, Ekbom T. et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ruilope LM, CocaA.,Volpe M.,Waeber B. ACE inhibition and cardiovascular mortality and morbidity in essential hypertension: the end of the search or a need for further investigations? Am J Hypertens 2002;15:367-71.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kaplan NM Management of hypertension in patients with type 2 diabetes mellitus: guidelines based on current evidence. Ann Intern Med 2001;135:1079-83.[Abstract/Free Full Text]
  • Blood Pressure Lowering Treatment Trialist Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000;355:1955-64.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Staessen JA, Wang YG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358:1305-15.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.1.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Svensson P., de Faire U., Sleight P. et al. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 2001;38:e28-e32.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic.TheAntihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial (ALLHAT).JAMA 2002;288:2981-97.[Abstract/Free Full Text]
  • Wing LMH, Reid CM, Ryan P. et al., for the Second Australian National Blood Pressure Study Group. N Engl J Med 2003;348:583-92.[Abstract/Free Full Text]
  • Pitt B., Poole-Wilson PA, Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial- the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cohn JN,Tognoni G. A randomised trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.[Abstract/Free Full Text]
  • Dahlöf B., Devereux RB, Kjeldsen SE et al., for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension (LIFE): randomised trial against atenolol. Lancet 2002;359:995-1003.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lindholm LH, Ibsen H., Dahlöf B. et al., for the LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension (LIFE): randomised trial against atenolol. Lancet 2002;359:1004-10.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lithell H., Hansson L., Skoog I. et al., for the SCOPE Study Group. The Study on COgnition and Prognosis in the Elderly (SCOPE). Principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-88.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pourdjabbar A., Lapointe N., Rouleau JL Angiotensin receptor blockers: powerful evidence with cardiovascular outcomes? Can J Cardiol 2002;18(suppl A):7A-14A.[Medline] [Order article via Infotrieve]
  • American Diabetes Association. Diabetic Nephropathy. Diabetes Care 2002;25(suppl 1):S85-S89.[CrossRef]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 4, No. 2, 74-79 (2003)
DOI: 10.3317/jraas.2003.016
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
G. Montalescot and J.-P. Collet
Preserving cardiac function in the hypertensive patient: why renal parameters hold the key
Eur. Heart J., December 2, 2005; 26(24): 2616 - 2622.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Ruilope, L. M
Right arrow Articles by Schiffrin, E. L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ruilope, L. M
Right arrow Articles by Schiffrin, E. L
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Blood Pressure Medicines
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement